Meldonium (Mildronate)
Metabolic Modulator | Endurance & Cardioprotection
Community Research
Join others researching Meldonium — share findings, ask questions, and learn from real experiences
Meldonium (marketed as Mildronate) is a cardioprotective and anti-ischemic drug developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. It is approved and widely prescribed in Latvia, Lithuania, Russia, and several other post-Soviet states for the treatment of coronary artery disease, heart failure, and cerebrovascular conditions. Meldonium has never been approved by the FDA or EMA, and it remains unavailable through conventional pharmaceutical channels in the United States and most of Western Europe. The drug gained worldwide notoriety in March 2016 when tennis star Maria Sharapova announced she had tested positive for meldonium after the World Anti-Doping Agency (WADA) added it to the Prohibited List effective January 1, 2016. Her positive test was far from isolated -- WADA reported that meldonium was the most common substance detected in doping control samples in early 2016, with hundreds of athletes across multiple sports testing positive, predominantly from Eastern European and Central Asian countries. This widespread use reflected meldonium's longstanding popularity among athletes in those regions, where it was both legally available by prescription and culturally accepted as a general-purpose cardioprotective and performance-enhancing agent. In the performance enhancement community, meldonium has attracted particular interest among anabolic steroid users seeking cardiac protection during cycles, given the well-documented cardiotoxic effects of supraphysiological androgen use including left ventricular hypertrophy, impaired diastolic function, and accelerated atherosclerosis.
Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time. Since carnitine is essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, reduced carnitine levels impair fatty acid beta-oxidation. This forces cells -- particularly cardiomyocytes and skeletal muscle cells -- to shift their metabolic fuel preference from fatty acid oxidation toward glucose oxidation. This metabolic shift is the cornerstone of meldonium's cardioprotective mechanism. Under ischemic conditions (reduced blood flow), fatty acid oxidation becomes metabolically inefficient and even harmful: incomplete fatty acid oxidation generates toxic intermediates (long-chain acylcarnitines and acyl-CoA species) that damage cell membranes and impair mitochondrial function. Glucose oxidation, by contrast, requires less oxygen per molecule of ATP produced and does not generate these toxic intermediates. By forcing the heart to rely more on glucose, meldonium effectively optimizes energy production under oxygen-limited conditions and reduces the accumulation of cardiotoxic lipid metabolites. Additionally, the accumulation of GBB that results from BBOX inhibition has been shown to stimulate nitric oxide (NO) production via an ester-mediated mechanism, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance. Meldonium also upregulates the expression of glucose transporter proteins (GLUT-1 and GLUT-4) and activates components of the Akt-dependent cardioprotective signaling pathway, further enhancing myocardial resistance to ischemic injury.
Molecular Data
Research Indications
Meldonium is increasingly used in the performance enhancement community as an adjunctive agent to protect the heart during anabolic steroid cycles. Supraphysiological androgen use is associated with left ventricular hypertrophy, impaired diastolic function, reduced ejection fraction, and accelerated atherosclerosis. Meldonium's ability to optimize cardiac energy metabolism and reduce toxic lipid intermediates may mitigate some of these effects, though direct clinical evidence in this specific context is limited to anecdotal and observational data.
By shifting fuel utilization from fatty acids toward glucose, meldonium may improve aerobic efficiency under submaximal exercise conditions. Athletes in Eastern European countries have used meldonium for decades to support training capacity and recovery. The metabolic shift may spare glycogen during prolonged activity and reduce post-exercise oxidative stress. This use drove WADA's decision to ban the substance.
In Baltic states and Russia, meldonium is an approved prescription drug for the treatment of stable angina pectoris and chronic ischemic heart disease. Clinical trials conducted primarily in Latvia and Russia have demonstrated reductions in angina frequency, improved exercise tolerance on treadmill testing, and reduced nitroglycerin consumption when meldonium is added to standard antianginal therapy.
Meldonium has been investigated as an adjunctive therapy in chronic heart failure, where impaired cardiac energy metabolism contributes to disease progression. Small trials have reported improvements in exercise capacity and quality-of-life scores when meldonium was added to standard heart failure regimens. Larger-scale, Western-standard randomized controlled trials are lacking.
The drug is prescribed in some Eastern European countries for acute and chronic cerebrovascular insufficiency. Its vasodilatory effects via nitric oxide stimulation and metabolic optimization may offer neuroprotective benefits during ischemic events. Evidence is primarily from non-Western clinical trials.
Dosing Protocols
Meldonium is primarily administered orally in capsule form. Standard pharmaceutical preparations (Mildronate) are available as 250 mg and 500 mg capsules. The drug has good oral bioavailability and reaches peak plasma concentrations within 1-2 hours of ingestion. Its relatively short half-life of 4-6 hours means some protocols split the daily dose into two administrations, though once-daily dosing is also common. An intravenous formulation exists and is used in clinical settings for acute cardiac events, but oral administration is the standard route for all performance enhancement and chronic use applications.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cardioprotection (On-Cycle Support) | 500 mg/day | Once daily or split into two doses (250 mg twice daily) | Oral (capsule) |
| Clinical Dose (Ischemic Heart Disease) | 500-1000 mg/day | Once daily or split into two doses | Oral (capsule) |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Mild gastrointestinal discomfort (nausea, dyspepsia, or stomach upset -- typically transient and dose-dependent)
- Occasional heartburn or acid reflux, especially at higher doses or when taken on an empty stomach
Stop Signs - Discontinue if:
- Signs of allergic reaction: rash, urticaria, swelling, difficulty breathing
- Severe or persistent gastrointestinal symptoms that do not resolve with dose adjustment
- Significant tachycardia or cardiac arrhythmia
- Unexplained muscle weakness or fatigue (may indicate excessive carnitine depletion)
Contraindications
- Known hypersensitivity to meldonium or any excipients
- Pregnancy or breastfeeding (insufficient safety data)
- Individuals under 18 years of age
- Severe hepatic or renal impairment (limited pharmacokinetic data in these populations)
- Increased intracranial pressure (listed as a contraindication in some regional prescribing information)
Quality Checklist
Good Signs
- Pharmaceutical-grade Mildronate capsules manufactured by Grindeks (the original Latvian pharmaceutical company)
- Clearly labeled with compound name, dose per capsule (250 mg or 500 mg), batch number, and expiration date
- Intact blister packaging with no signs of tampering or moisture damage
- Sourced from a licensed pharmacy in a country where the drug is approved (Latvia, Lithuania, Russia, etc.)
- Third-party lab testing confirms identity and potency if purchased from a non-pharmacy source
Warning Signs
- Loose capsules or tablets not in original pharmaceutical packaging
- No batch number or expiration date visible
- Purchased from an unverified online supplier without reputation or reviews
- Priced significantly below the typical cost of genuine Grindeks-manufactured product
- Labeled as a research chemical or supplement rather than a pharmaceutical product
Bad Signs
- Capsules show discoloration, unusual odor, or signs of degradation
- No labeling, incorrect labeling, or packaging in a language inconsistent with claimed country of origin
- Third-party testing reveals wrong compound, significant underdosing, or contamination
- Supplier has no verifiable reputation or has been flagged for selling counterfeit pharmaceuticals
- Product arrives with broken seals, damaged packaging, or evidence of repackaging
References
- Mildronate: An Antiischemic Drug for Neurological IndicationsDambrova, M., Makrecka-Kuka, M., Vilskersts, R., et al.CNS Drug Reviews (2004)
Comprehensive review of meldonium's mechanism of action and clinical applications. Confirmed that meldonium inhibits carnitine biosynthesis and transport, shifting cellular energy metabolism from fatty acid oxidation to glucose oxidation. Summarized evidence supporting its use in ischemic heart disease and cerebrovascular conditions.
- Mildronate, a Novel Fatty Acid Oxidation Inhibitor and Antianginal Agent, Reduces Myocardial Infarct Size Without Affecting HemodynamicsSesti, C., Simkhovich, B.Z., Kalvinsh, I., Kloner, R.A.Journal of Cardiovascular Pharmacology (2006)
Demonstrated that meldonium reduced myocardial infarct size in a rat model of ischemia-reperfusion injury without significant hemodynamic effects. Supported the hypothesis that metabolic modulation via carnitine pathway inhibition provides direct cardioprotection independent of changes in blood pressure or heart rate.
- Mildronate Improves Peripheral Circulation in Patients with Chronic Heart FailureDzerve, V., MILSS I Study GroupJournal of Cardiac Failure (2005)
Randomized controlled trial showing that meldonium at 1000 mg/day improved exercise tolerance and quality of life in patients with chronic heart failure compared to placebo. The study supported meldonium as an adjunctive therapy for heart failure management.
- Meldonium Use in Athletes -- A Reason for Concern?Greenblatt, H.K., Greenblatt, D.J.British Journal of Clinical Pharmacology (2016)
Published in response to the WADA ban and the Sharapova case, this review summarized meldonium's pharmacology, clinical evidence, and the rationale for its prohibition in sport. Noted the discrepancy between meldonium's widespread use in Eastern Europe and the lack of large-scale Western clinical trials, and discussed the challenges of establishing performance-enhancing effects definitively.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.